title: The inactive form of glycogen synthase kinase-3β is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice.
abstract: Galectin-3 has been implicated in the tumor development via its mediation of the Wnt signaling pathway. Likewise, glycogen synthase kinase-3beta (GSK3β) also plays a role in the Wnt signaling pathway by controlling the levels of cytoplasmic beta-catenin. Altered GSK3β expression has been described in various tumors, but to date, there are no studies evaluating its expression in models of oral carcinogenesis. Additionally, it is unknown whether the absence of galectin-3 regulates the expression of GSK3β. To this end, Gal3-deficient (Gal3(-/-)) and wild-type (Gal3(+/+)) male mice were treated with 4NQO for 16 weeks and sacrificed at week 16 and 32. The tongues were removed, processed, and stained with H&E to detect dysplasias and carcinomas. An immunohistochemical assay was performed to determine the level of P-GSK3β-Ser9 expression in both groups. Carcinomas were more prevalent in Gal3(+/+) than Gal3(-/-) mice (55.5% vs. 28.5%), but no statistical difference was reached. In the dysplasias, the proportion of cells positive for P-GSK3β-Ser9 was slightly higher in Gal3(+/+) than Gal3(-/-) mice (63% vs. 61%). In the carcinomas, a significant difference between Gal3(+/+) and Gal3(-/-) mice was found (74% vs. 59%; p=0.02). P-GSK3β-Ser9-positive cells slightly decreased from the progression of dysplasias to carcinomas in Gal3(-/-) mice (61% vs. 59%; p>0.05). However, a significant increase in P-GSK3β-Ser9 expression was observed from dysplasias to carcinomas in Gal3(+/+) mice (63% vs. 74%; p=0.01). In conclusion, these findings suggest that fully malignant transformation of the tongue epithelium is associated with increased P-GSK3β-Ser9 expression in Gal3(+/+) mice, but not in Gal3(-/-) mice.
authors.affiliation: Uberlândia Federal University, School of Medicine, Uberlândia, Brazil.
authors.forename: Daniella Fernandes
authors.initials: DF
authors.lastname: Mendonça
authors.forename: Roger
authors.initials: R
authors.lastname: Chammas
authors.forename: Fu-Tong
authors.initials: FT
authors.lastname: Liu
authors.forename: Suely
authors.initials: S
authors.lastname: Nonogaki
authors.forename: Sergio Vitorino
authors.initials: SV
authors.lastname: Cardoso
authors.forename: Adriano Mota
authors.initials: AM
authors.lastname: Loyola
authors.forename: Paulo Rogério
authors.initials: PR
authors.lastname: de Faria
mesh_terms: D015112:4-Nitroquinoline-1-oxide / Q000633:toxicity; D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D002273:Carcinogens / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000473:pathology; D002467:Cell Nucleus / Q000201:enzymology / Q000473:pathology; D003593:Cytoplasm / Q000201:enzymology / Q000473:pathology; D037502:Galectin 3 / Q000172:deficiency / Q000378:metabolism*; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D011230:Precancerous Conditions / Q000201:enzymology* / Q000473:pathology; D014062:Tongue Neoplasms / Q000201:enzymology* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D002273:Carcinogens; D037502:Galectin 3; D015112:4-Nitroquinoline-1-oxide; D000071679:Glycogen Synthase Kinase 3 beta; C000605507:Gsk3b protein, mouse; D038362:Glycogen Synthase Kinase 3